第六届癌症免疫治疗会议（ITOC）：进展与展望——会议报告。

Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.

机构信息

Human Cancer Immunology, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Department of Surgery, Medical University of Vienna, Vienna, Austria.

出版信息

J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268.

DOI:10.1136/jitc-2019-000268

PMID:32114499

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7057436/

Abstract

Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals. In this complex environment, scientists rely on cutting edge conferences to stay informed. The Immunotherapy of Cancer (ITOC) conference was established jointly with the Society of the Immunotherapy of Cancer to bring the European researchers together. In its sixth edition, the ITOC conference has recently been held in Vienna, Austria.

摘要

免疫疗法已成为癌症治疗的前沿领域，新疗法的批准速度不断加快，这一点得到了充分体现。在这种复杂的环境下，科学家们依靠尖端会议来获取信息。癌症免疫疗法（ITOC）会议是与癌症免疫治疗学会联合举办的，旨在将欧洲研究人员聚集在一起。该会议最近在奥地利维也纳举行了第六届。